242 related articles for article (PubMed ID: 31618685)
1. LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease.
Rocha EM; De Miranda BR; Castro S; Drolet R; Hatcher NG; Yao L; Smith SM; Keeney MT; Di Maio R; Kofler J; Hastings TG; Greenamyre JT
Neurobiol Dis; 2020 Feb; 134():104626. PubMed ID: 31618685
[TBL] [Abstract][Full Text] [Related]
2. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
De Miranda BR; Castro SL; Rocha EM; Bodle CR; Johnson KE; Greenamyre JT
Neurobiol Dis; 2021 Jun; 153():105312. PubMed ID: 33636387
[TBL] [Abstract][Full Text] [Related]
3. Exploring the focal role of LRRK2 kinase in Parkinson's disease.
Kumar S; Behl T; Sehgal A; Chigurupati S; Singh S; Mani V; Aldubayan M; Alhowail A; Kaur S; Bhatia S; Al-Harrasi A; Subramaniyan V; Fuloria S; Fuloria NK; Sekar M; Abdel Daim MM
Environ Sci Pollut Res Int; 2022 May; 29(22):32368-32382. PubMed ID: 35147886
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants.
Ilieva NM; Hoffman EK; Ghalib MA; Greenamyre JT; De Miranda BR
Neurobiol Dis; 2024 Jun; 196():106522. PubMed ID: 38705492
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
6. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 and idiopathic Parkinson's disease.
Rocha EM; Keeney MT; Di Maio R; De Miranda BR; Greenamyre JT
Trends Neurosci; 2022 Mar; 45(3):224-236. PubMed ID: 34991886
[TBL] [Abstract][Full Text] [Related]
8. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 activation in idiopathic Parkinson's disease.
Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
[TBL] [Abstract][Full Text] [Related]
10. Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo.
Dodson MW; Leung LK; Lone M; Lizzio MA; Guo M
Dis Model Mech; 2014 Dec; 7(12):1351-63. PubMed ID: 25288684
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 and the Endolysosomal System in Parkinson's Disease.
Erb ML; Moore DJ
J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
[TBL] [Abstract][Full Text] [Related]
13. Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice.
Giaime E; Tong Y; Wagner LK; Yuan Y; Huang G; Shen J
Neuron; 2017 Nov; 96(4):796-807.e6. PubMed ID: 29056298
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells.
Ho DH; Nam D; Seo MK; Park SW; Seol W; Son I
Oxid Med Cell Longev; 2021; 2021():9969842. PubMed ID: 34306319
[TBL] [Abstract][Full Text] [Related]
15. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
[TBL] [Abstract][Full Text] [Related]
16. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
18. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
Albanese F; Domenicale C; Volta M; Morari M
Biochem Soc Trans; 2022 Feb; 50(1):621-632. PubMed ID: 35225340
[TBL] [Abstract][Full Text] [Related]
19. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E
Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
